Browse > Article

A Case of Tamoxifen-Associated Rapid Growing and Multiple Endometrial Polyps  

Lee, Hee-Jun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Kim, Hoon (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Ku, Seung-Yup (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Han, Won-Shik (Department of Surgery, Seoul National University College of Medicine)
Kim, Seok-Hyun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Choi, Young-Min (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Kim, Jung-Gu (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Moon, Shin-Yong (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
Publication Information
Clinical and Experimental Reproductive Medicine / v.37, no.2, 2010 , pp. 173-179 More about this Journal
Abstract
The antiestrogen tamoxifen is currently the most commonly used adjuvant treatment of breast cancer with antiestrogenic effect on mammary tissue. However, it is also associated with endometrial abnormalities, including hyperplasia, polyps, carcinoma, mostly interpreted as evidence of estrogenic effect on the endometrium. Previously, tamoxifen-associated polyp in breast cancer has been reported in the literature. Most studies had a long follow-up period and tamoxifen-associated polyp developed more than 1 year after tamoxifen treatment. In this case, we report an unusual case of rapid growing and multiple endometrial polyps that were developed only after 3 months' tamoxifen treatment in a postmenopausal breast cancer patient who received quadrant mastectomy with a brief review of literature.
Keywords
Tamoxifen; Endometrial polyp;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Goncalves MA, Goncalves WJ, Matias MM, Nazario AC, de Lima GR, Baracat EC. Hysteroscopic evaluation of the endometrium of post-menopausal patients with breast cancer before and after tamoxifen use. Int J Gynaecol Obstet 1999; 66: 273-9.   DOI   ScienceOn
2 Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol 2001; 97: 855-66.   DOI   ScienceOn
3 Le Donne M, Lentini M, De Meo L, Benedetto V, Mesiti M. Uterine pathologies in patients undergoing tamoxifen therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings. Eur J Gynaecol Oncol 2005; 26: 623-6.
4 Tepper R, Beyth Y, Altaras MM, Zalel Y, Shapira J, Cordoba M, et al. Value of sonohysterography in asymptomatic postmenopausal tamoxifen-treated patients. Gynecol Oncol 1997; 64: 386-91.   DOI   ScienceOn
5 ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Obstet Gynecol 2006; 107: 1475-8.   DOI   ScienceOn
6 Senkus-Konefka E, Konefka T, Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev 2004; 30: 291-301.   DOI   ScienceOn
7 Antunes A Jr, Costa-Paiva L, Arthuso M, Costa JV, Pinto-Neto AM. Endometrial polyps in pre- and postmenopausal women: factors associated with malignancy. Maturitas 2007; 57: 415 -21.   DOI   ScienceOn
8 Cohen I, Bernheim J, Azaria R, Tepper R, Sharony R, Beyth Y. Malignant endometrial polyps in postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 1999; 75: 136-41.
9 Qureshi A, Bukhari F, Pervez S. Spectrum of tamoxifen associated endometrial pathology in breast cancer patients. J Pak Med Assoc 2009; 59: 249-50.
10 Markovitch O, Tepper R, Fishman A, Shapira J, Aviram R, Cohen I. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecol Oncol 2004; 95: 456-62.   DOI   ScienceOn
11 Lin MC, Gosink BB, Wolf SI, Feldesman MR, Stuenkel CA, Braly PS, et al. Endometrial thickness after menopause: effect of hormone replacement. Radiology 1991; 180: 427-32.   DOI
12 Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 2000; 22: 1-11.   DOI   ScienceOn
13 Dibi RP, Zettler CG, Pessini SA, Ayub AV, de Almeida SB, da Silveira GP. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer. Menopause 2009; 16: 293-300.   DOI   ScienceOn
14 Al-Brahim N, Elavathil LJ. Metastatic breast lobular carcinoma to tamoxifen-associated endometrial polyp: case report and literature review. Ann Diagn Pathol 2005; 9: 166-8.   DOI   ScienceOn
15 Cohen I, Azaria R, Bernheim J, Shapira J, Beyth Y. Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen. Cancer 2001; 92: 1151-5.   DOI   ScienceOn
16 Maugeri G, Nardo LG, Campione C, Nardo F. Endometrial lesions after tamoxifen therapy in breast cancer women. Breast J 2001; 7: 240-4.   DOI   ScienceOn
17 Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004; 94: 256-66.   DOI   ScienceOn
18 Mourits MJ, Ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG, Hollema H. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol 2002; 55: 514-9.   DOI   ScienceOn
19 Gregoriou O, Konidaris S, Vrachnis N, Bakalianou K, Salakos N, Papadias K, et al. Clinical parameters linked with malignancy in endometrial polyps. Climacteric 2009; 12: 454-8.   DOI   ScienceOn